Day 1 Day 2 Day 3 Day 4 Day 5 TR Gün 2
OncoHub OncoHub.ai
Oncology Scientific Bulletin
ASCO 2026 · Day 2 Summary
ASCO Annual Meeting · Day 2 Digest

ASCO 2026 — End-of-Day Summary

An abstract digest clustered by cancer type and ranked by clinical priority. Numerical results (HR, PFS, OS) are preserved; reliability caveats are embedded within each study's card.

Date: 30 May 2026 Scope: ~55 presentations + gated/inaccessible titles Layout: Cancer type → clinical priority
Day's Highlights
High-priority (practice-changing) studies — click to jump to the card.
  1. OPTIMA — Test-directed endocrine-only therapy (chemo avoidance)Abstract 500Patients with ROR ≤60 tumors (including premenopausal with OFS) can safely avoid chemotherapy.
  2. KEYNOTE-522 — Neoadjuvant/adjuvant pembrolizumab (7.8-yr final)Abstract 507Pembrolizumab sustains long-term EFS and OS benefit.
  3. lidERA BC — Adjuvant giredestrant vs SOC endocrine therapyAbstract 502IDFS/DRFI benefit regardless of menopausal status; fewer treatment discontinuations vs AI.
  4. FUZUPRO — Fuzuloparib + abiraterone/prednisone (1L)Abstract 5008rPFS benefit across the whole population; more pronounced in DRD-positive patients.
  5. Peak — Bezuclastinib + sunitinib vs sunitinib (GIST, 2L)Abstract 11500The combination reduces the risk of progression/death by 50% in 2L GIST.
  6. RINGSIDE Phase 3 — Varegacestat vs placebo (desmoid)NCT04871282The highest ORR reported for systemic Phase 3 desmoid therapy.
  7. SUNMO — Mosunetuzumab + polatuzumab vs R-GemOxAbstract 7007Marked efficacy in 2L; low toxicity.
Filter

🎀 Breast Cancer

9 studies

OPTIMA — Test-directed endocrine-only therapy (chemo avoidance)

Abstract 500
● High priorityPhase 3 · non-inferiorityProsigna ROR · de-escalation

Indication: High clinical-risk ER+/HER2−, mostly node-positive early breast cancer

Key finding: 4,429 patients. At Prosigna ROR ≤60, test-directed endocrine-only therapy was non-inferior to chemo+endocrine: 5-yr IBCFS 91.5% (control) vs 90.4%, HR 0.99 (90% CI 0.81–1.20), NI p=0.013; in the low-ROR population 94.9% vs 93.7%, HR 1.06 (90% CI 0.78–1.46), NI p=0.0051.

Clinical relevance: Patients with ROR ≤60 tumors (including premenopausal with OFS) can safely avoid chemotherapy.

Source: ASCO Abstract 500

KEYNOTE-522 — Neoadjuvant/adjuvant pembrolizumab (7.8-yr final)

Abstract 507
● High priorityPhase 3 · final analysisanti-PD-1 + chemo

Indication: High-risk early-stage TNBC

Key finding: Median follow-up 93.8 mo; 7-yr EFS 78.3% vs 69.8% (HR 0.68, 0.54–0.86); 7-yr OS 85.1% vs 77.2% (HR 0.64, 0.49–0.85); G≥3 treatment-related AE 77.1% vs 73.3%; any-grade immune-mediated AE 35.0% vs 13.1%.

Clinical relevance: Pembrolizumab sustains long-term EFS and OS benefit.

Source: ASCO Abstract 507

lidERA BC — Adjuvant giredestrant vs SOC endocrine therapy

Abstract 502
● High priorityPhase 3Oral SERD

Indication: ER+/HER2−, stage I–III early breast cancer

Key finding: Pre-menopausal IDFS HR 0.65 (3-yr 94.0% vs 91.5%), DRFI HR 0.58; post-menopausal IDFS HR 0.74 (91.3% vs 88.3%), DRFI HR 0.76; metastatic-disease risk reduction pre-M 42%, post-M 24%.

Clinical relevance: IDFS/DRFI benefit regardless of menopausal status; fewer treatment discontinuations vs AI.

Source: ASCO Abstract 502

NCT01019616 — Non-cross-resistant adjuvant chemo (10-yr)

Abstract 506
● Medium priorityPhase 3 · long-termAdjuvant chemo

Indication: HR+/HER2−, node+ residual disease after NAC

Key finding: 135-mo median follow-up; 10-yr OS 89.9% vs 82.9%, adjusted HR 0.56 (95% CI 0.32–0.99; p=0.048); residual node+ subgroup OS HR 0.47.

Clinical relevance: Long-term OS benefit of non-cross-resistant chemotherapy demonstrated.

Source: ASCO Abstract 506

NATALEE correlative analysis — Adjuvant ribociclib (PAM50)

Abstract 501
● Medium priorityPhase 3 biomarker subanalysisGene expression

Indication: HR+/HER2− stage II/III EBC, adjuvant ribociclib

Key finding: ITT HR 0.71; biomarker population HR 0.72. PAM50 prognostic HRs: LumA reference, LumB 1.39, HER2E 2.62, BSL 3.92. RIB benefit across all subtypes; subtype × treatment interaction p=0.34.

Clinical relevance: Ribociclib benefit is consistent across all PAM50 subtypes.

Source: ASCO Abstract 501

AXSANA / EUBREAST-03 — Axillary response after NACT

Abstract 505
● Medium priorityProspective · 5,262 patientsSurgical de-escalation

Indication: Node-positive breast cancer, after NACT

Key finding: ypN0 rate: HR− HER2+ 86.1%, HR+ HER2+ 70.7%, TNBC 68.5%, HR+ HER2− 30.5% (p<0.001); ≥4 suspicious nodes vs 1–3 nodes 53.6% vs 54.4% (p=0.670).

Clinical relevance: Axillary response depends on tumor biology, not the initial nodal count.

Source: ASCO Abstract 505

OPBC-02 / PREPEC — Pre- vs sub-pectoral implant reconstruction

Abstract 504
● Medium priorityPhase 3 randomizedPRO / quality of life

Indication: Implant reconstruction after mastectomy

Key finding: 24-mo physical well-being pre-pectoral 79.2 vs sub-pectoral 74.3 (difference 4.8; 95% CI 1.0–8.7; p=0.01); implant loss/exchange within 24 mo 21.1% vs 14.5%.

Clinical relevance: Pre-pectoral improves long-term quality of life but carries a higher implant-loss risk.

Source: ASCO Abstract 504

SENOMAC — Omission of axillary dissection in SLN macrometastasis

LBA503
● WatchPhase 3 randomizedGated · full text unavailable

Indication: Breast cancer with sentinel-node macrometastasis

Key finding: Randomized results for omitting complete axillary dissection; full text was not available in the source.

Clinical relevance: Unclear; must be verified against the official presentation/publication full text.

Gated: "Full text available May 30 08:00 AM ET" — numerical results not in this digest.

Source: ASCO Abstract LBA503

Anbenitamab vs THP — Neoadjuvant (HER2+)

LBA660
● WatchPhase 3 randomizedGated · full text unavailable

Indication: HER2+ early/locally advanced breast cancer

Key finding: Neoadjuvant anbenitamab vs THP comparison; full text was not available in the source.

Clinical relevance: Unclear; must be verified against the full text.

Gated: Full text unavailable.

Source: ASCO Abstract LBA660

⚕ Prostate Cancer

8 studies

FUZUPRO — Fuzuloparib + abiraterone/prednisone (1L)

Abstract 5008
● High priorityPhase 3PARP inhibitor + ARPI

Indication: 1L metastatic castration-resistant prostate cancer (mCRPC)

Key finding: Median rPFS 24.8 vs 19.9 mo (HR 0.71; 95% CI 0.55–0.91; 1-sided p=0.0034); DRD-positive subgroup 27.7 vs 13.9 mo (HR 0.51; p=0.0039); G≥3 anemia 20.1%.

Clinical relevance: rPFS benefit across the whole population; more pronounced in DRD-positive patients.

Source: ASCO Abstract 5008

ENZAMET / Decipher GC — Predicting docetaxel benefit

Abstract 5001
● Medium priorityPhase 3 secondary analysisGenomic classifier (Level 1B)

Indication: Metastatic hormone-sensitive prostate cancer (mHSPC)

Key finding: At Decipher GC >0.85, ADT+ENZ aHR 2.31 (95% CI 1.26–4.21; p=0.007); with ADT+ENZ+DOC aHR 1.08 (0.63–1.86); p-interaction = 0.043.

Clinical relevance: DGC >0.85 may identify patients who benefit from adding docetaxel to ADT+ENZ.

Source: ASCO Abstract 5001

ARACOG / AFT-47 — Darolutamide vs enzalutamide (cognition)

Abstract 5005
● Medium priorityPhase 2 randomizedCognitive endpoint

Indication: mHSPC/mCRPC/nmCRPC

Key finding: At week 24, median change in the maximally affected cognitive domain −15.8% vs −36.1% (p=0.009); all crossovers were ENZ→DAR.

Clinical relevance: Darolutamide has a better cognitive profile than enzalutamide.

Source: ASCO Abstract 5005

A-DREAM / Alliance A032101 — Planned ADT interruption

Abstract 5004
● Medium priorityPhase 2Treatment de-escalation

Indication: mHSPC, exceptional responders to TS+ARPI

Key finding: At 18 months, 41% (32/78) remained treatment-free with eugonadal testosterone (80% CI 33.5–48.9; 1-sided p=0.0249); 67% recovered testosterone.

Clinical relevance: Planned treatment interruption is feasible in selected patients.

Source: ASCO Abstract 5004

ZZFIRST — Enzalutamide + talazoparib (high-volume mHNPC)

Abstract 5006
● WatchPhase 2 randomizedARPI + PARP inh.AML signal

Indication: High-volume metastatic hormone-naïve prostate cancer (mHNPC)

Key finding: 12-mo PSA<0.2 response rate 73% (95% CI 55.9–86.2; p<0.001); median rPFS 45.3 vs 31.1 mo (HR 0.62; 95% CI 0.28–1.37); 2 patients developed AML after prolonged talazoparib exposure.

Clinical relevance: Promising antitumor activity; the AML signal must be monitored.

Caution: 2 AML cases reported after prolonged talazoparib exposure.

Source: ASCO Abstract 5006

ST-DoxPCa — Spatial transcriptomics + AI pathology biomarker

Abstract 5002
● WatchBiomarker developmentAI · H&E-based

Indication: mHSPC (CHAARTED), prediction of docetaxel benefit

Key finding: In ST-DoxPCa-positive patients ADT+DOC HR 0.53 (95% CI 0.31–0.90; p=0.018); in negatives HR 1.32 (0.74–2.34; p=0.34).

Clinical relevance: Potential for personalized treatment intensification with an H&E-based biomarker.

Source: ASCO Abstract 5002

Clinical-Transcriptomic Risk Stratification

Abstract 5000
● WatchNRG/RTOG pooled analysisGenomic classifier

Indication: High-risk localized prostate cancer

Key finding: GC continuous MFS HR 1.19 (95% CI 1.10–1.29, p<0.001); OS HR 1.18; combined score ≥3 subgroup had a STAMPEDE M0-control-like prognosis.

Clinical relevance: Could expand the AAP-candidate pool by ~20%; 25% of very-high-risk patients could avoid AAP.

Source: ASCO Abstract 5000

TALAPRO-3 — Talazoparib + enzalutamide (HRR-altered mCSPC)

LBA5007
● WatchPhase 3ARPI + PARP inh.Gated · full text unavailable

Indication: HRR gene-altered metastatic castration-sensitive prostate cancer (mCSPC)

Key finding: Talazoparib + enzalutamide combination; full results released 30 May 08:00 ET, the abstract text was not available in this digest's source.

Clinical relevance: Unclear; must be verified against the full text.

Gated: Numerical results not in this digest.

Source: ASCO Abstract LBA5007

🧠 CNS · Brain Metastasis & Glioma

7 studies

NEO-TACTICS — Neoadjuvant FSRT + resection

Abstract 2003
● Medium priorityPhase 2Neoadjuvant stereotactic RT

Indication: Brain metastases 2–5 cm

Key finding: 6-mo surgical-bed local recurrence cumulative incidence 4.3% (95% CI 0–10.1); no LMD at 6 or 12 mo; 12-mo LR 16.4%; no symptomatic radionecrosis; 12-mo OS 76.5%.

Clinical relevance: A promising alternative to post-op FSRT.

Source: ASCO Abstract 2003

COG-SRS — Connectome-preserving SRS

Abstract 2002
● Medium priorityPhase 2Cognition-preserving RT

Indication: Intracranial lesions (mostly brain metastases)

Key finding: At month 3, 74% of patients had stable/improved cognitive performance; global composite Z difference +0.38 (p=0.001); 1-yr local control 98.5%.

Clinical relevance: Cognitive preservation can be achieved without compromising oncologic control.

Source: ASCO Abstract 2002

NIBIT-M2 — Ipilimumab + nivolumab (10-yr follow-up)

Abstract 2008
● Medium priorityPhase 3 · long-termdual IO

Indication: Melanoma with asymptomatic brain metastases

Key finding: Arm C (I+N) median OS 29.2 mo; 10-yr OS 31.2% (95% CI 13.0–49.4); in patients with low cfDNA tumor fraction median OS 22.3 vs 8.2 mo (p=0.033).

Clinical relevance: Long-term efficacy of I+N; cfDNA biomarker potential.

Source: ASCO Abstract 2008

JCOG1703 / MACS — Carmustine wafer + standard CRT (NEGATIVE)

Abstract 2001
● Medium priorityPhase 3Implanted chemotherapyNo OS benefit

Indication: Newly diagnosed GBM, ≥90% resection

Key finding: Median OS 21.7 vs 27.7 mo, HR 0.907 (91.5% CI 0.691–1.192; p=0.269); median PFS 9.5 vs 10.4 mo, HR 0.867.

Clinical relevance: Adding a carmustine wafer provides no OS benefit.

Source: ASCO Abstract 2001

MAGMA — Platform Phase 3, early vs extended TMZ

Abstract 2004
● Medium priorityPlatform Phase 3Primary nonsignificant

Indication: Newly diagnosed GBM

Key finding: Q1 (early TMZ): median OS 16 vs 20 mo, HR 1.18 (0.89–1.56), p=0.24. Q2 (extended TMZ): 20 vs 18 mo, HR 0.82 (0.63–1.06), p=0.13; post-multivariate HR 0.73 (0.56–0.95).

Clinical relevance: Early TMZ does not improve OS; uncertainty remains for adjuvant TMZ beyond 6 cycles.

Caution: Q2 not significant in the primary analysis; benefit only borderline after multivariate adjustment.

Source: ASCO Abstract 2004

OLA-TMZ-RTE-01 — Olaparib + TMZ + RT (Stupp)

Abstract 2005
● WatchPhase 1/2aPARP inh. + CRTNon-randomized

Indication: Unresectable/partially resected high-grade glioma

Key finding: 12-mo OS 69.1% (95% CI 59–81); median OS 18.4 mo; H0 rejected (Z=1.29); one toxic death (febrile aplasia).

Clinical relevance: Potential survival improvement in poor-prognosis unresectable GBM.

Preliminary: Phase 2a stage, no randomized comparison.

Source: ASCO Abstract 2005

Glioblastoma Neoantigen Vaccine (NeoVax + pembrolizumab)

Abstract 2006
● WatchPhase 1Personalized neoantigen vaccine

Indication: Newly diagnosed GBM

Key finding: Median OS MGMT-methylated 36.9 vs 25.3 mo (matched control); MGMT-unmethylated 19.0 vs 16.7 mo; in ex vivo immune responders OS improvement HR 0.26 (95% CI 0.09–0.77, p=0.015).

Clinical relevance: A personalized neoantigen vaccine can induce immune response; associated with OS.

Preliminary: Phase 1, small scale; matched-control comparison.

Source: ASCO Abstract 2006

🦴 Sarcoma & GIST

9 studies

Peak — Bezuclastinib + sunitinib vs sunitinib (GIST, 2L)

Abstract 11500
● High priorityPhase 3KIT inhibitor combination

Indication: Advanced GIST, post-imatinib 2L

Key finding: Median PFS 16.5 (95% CI 13.8–19.2) vs 9.2 mo (7.2–11.0), HR 0.50 (0.39–0.65; P<0.0001); ORR 46% vs 26% (risk difference 20%; P<0.0001).

Clinical relevance: The combination reduces the risk of progression/death by 50% in 2L GIST.

Maturity: OS data immature.

Source: ASCO Abstract 11500

RINGSIDE Phase 3 — Varegacestat vs placebo (desmoid)

NCT04871282
● High priorityPhase 3Gamma-secretase inhibitor

Indication: Progressive desmoid tumor

Key finding: PFS HR 0.16 (95% CI 0.07–0.38; P<0.0001); confirmed ORR 55.7% vs 9.1% (P<0.0001); 24-wk tumor-volume change LS mean −109.6 vs +122.8 cm³; worst-pain (WPI) change −2.24 vs +0.18 (P<0.0001); ovarian toxicity in premenopausal women 20/36 (56%).

Clinical relevance: The highest ORR reported for systemic Phase 3 desmoid therapy.

Caution: High ovarian toxicity (56%) in premenopausal women.

Source: ASCO Abstract / NCT04871282

ChonDRAgon — Ozekibart (INBRX-109)

Abstract 11504
● Medium priorityPhase 2 randomizedDR5 agonist

Indication: Advanced conventional chondrosarcoma

Key finding: DCR 54.0% vs 27.5% (P=0.0005); ORR 5.8% vs 0 (P=0.0433); median time to pain worsening 2.76 vs 1.41 mo (HR 0.605; P=0.0033).

Clinical relevance: A potential first standard of care in this population.

Maturity: OS data immature.

Source: ASCO Abstract 11504

2ND-STEP / JCOG1802 — STS 2L (pazopanib selected)

Abstract 11508
● Medium priorityPhase 2 randomized3-arm selection

Indication: Advanced soft-tissue sarcoma (STS), 2L

Key finding: Median PFS trabectedin 2.9, eribulin 2.2, pazopanib 3.8 mo; pazopanib HR (vs trabectedin) 0.99 (0.63–1.56); DCR pazopanib 64.9%; mOS pazopanib 15.7 mo.

Clinical relevance: Pazopanib was selected for the Phase 3 comparison.

Source: ASCO Abstract 11508

Velzatinib / StrateGIST 1 — Broad-coverage KIT/PDGFRA inhibitor

Abstract 11501
● WatchPhase 1/1bKIT/PDGFRA inh.1L responses unconfirmed

Indication: Advanced GIST, 1L and 2L

Key finding: 2L median PFS 13.7 mo (95% CI 7.4–18.4); 1L ORR 61% (11/18); 2L ORR 35%; 2L dose reduction 6%.

Clinical relevance: Broad mutation coverage; rationale for Phase 3.

Preliminary: The large majority of 1L responses are unconfirmed.

Source: ASCO Abstract 11501

VEBrant — Vebreltinib (clear cell sarcoma)

Abstract 11503
● WatchPhase 2MET inhibitorSevere rash

Indication: Advanced clear cell sarcoma

Key finding: ORR 41.2% (7/17); DCR 70.6%; median PFS 4.14 mo; 6-mo PFS 42.8%; in the immunotherapy combination 4 patients discontinued for G4 rash.

Clinical relevance: Meaningful antitumor activity; risk of severe rash.

Source: ASCO Abstract 11503

Afami-cel — MAGE-A4 TCR-T (synovial sarcoma)

Abstract 11505
● WatchPhase 1+2 pooledTCR-T cell therapy

Indication: Advanced synovial sarcoma, MAGE-A4+/HLA-A*02

Key finding: ORR 43.8% (95% CI 35.8–52.0); median DoR 7.1 mo; median OS 18.7 mo; in RECIST responders median OS 37.5 mo; CRS 73.2%.

Clinical relevance: Meaningful survival in this rare population.

Source: ASCO Abstract 11505

APROMISS — Catequentinib (ASPS)

Abstract 11502
● WatchPhase 3Multi-kinase inhibitorORR threshold not met

Indication: Advanced/metastatic alveolar soft part sarcoma (ASPS)

Key finding: ORR 26.8% (95% CI 15.8–40.3; below the pre-specified 31% threshold); mDOR 22.57 mo; mPFS 18.33 mo; mOS 59.27 mo; G≥3 TRAE 48.2%; one G5 event.

Clinical relevance: The ORR threshold was not met, but disease control and survival are prolonged.

Caution: The primary ORR threshold (31%) was not met; benefit is argued via DCR and survival.

Source: ASCO Abstract 11502

Trabectedin + RT — Neoadjuvant (retroperitoneal L-sarcoma)

Abstract 11507
● WatchPhase 1/2Chemoradiotherapy

Indication: Resectable retroperitoneal liposarcoma (DDLPS, LMS)

Key finding: Complete resection 96%; Choi PR 26.7%; 3-yr PFS 70% (95% CI 56–83); 3-yr OS 85% (75–95); G3/4 neutropenia 21.4%.

Clinical relevance: Rationale for Phase 3.

Source: ASCO Abstract 11507

🧬 Lymphoma · Bispecific / CAR-T & Novel Regimens

9 studies

SUNMO — Mosunetuzumab + polatuzumab vs R-GemOx

Abstract 7007
● High priorityPhase 3CD20×CD3 BsAb + ADC

Indication: R/R LBCL, ASCT-ineligible

Key finding: Median PFS 11.6 vs 3.8 mo (HR 0.41; 95% CI 0.28–0.60); 2L: 17.6 vs 3.6 mo (HR 0.38); 3L+: HR 0.48; 2-yr PFS (2L) 40.3% vs 20.1%; G≥2 CRS 4%; no ICANS reported.

Clinical relevance: Marked efficacy in 2L; low toxicity.

Source: ASCO Abstract 7007

Glofitamab — Fixed-duration (R/R MCL)

Abstract 7006
● Medium priorityPhase 1/2 · long-termCD20×CD3 BsAb

Indication: R/R mantle cell lymphoma (MCL)

Key finding: Median follow-up 41.5 mo; ORR 82%, CR 77%; median DoCR 40.8 mo; in the post-BTKi subgroup ORR 73.5%, CR 70.6%; G3-4 CRS 11.6%.

Clinical relevance: Durable efficacy in post-BTKi MCL.

Source: ASCO Abstract 7006

LINCH — Linperlisib + CHOP (newly diagnosed PTCL)

Abstract 7004
● WatchPhase 1b/2PI3Kδ inh. + chemoPreliminary

Indication: Newly diagnosed peripheral T-cell lymphoma (PTCL)

Key finding: CR after 6 cycles 55.9% (19/34); ORR 67.6%; G≥3 TEAE 55.9%.

Clinical relevance: Promising; a Phase 3 randomized trial has started (NCT06548347).

Preliminary: Phase 1b/2; only 34/44 evaluable.

Source: ASCO Abstract 7004

PRIMAVERA / AZD3470 — PRMT5 inhibitor

Abstract 7003
● WatchPhase 1PRMT5 inh. (MTAP-deficient)

Indication: R/R classic Hodgkin lymphoma (MTAP-deficient)

Key finding: At ≥DL7 (n=10) ORR 80%, CR 50%; G≥3 TEAE 28%; no DLTs.

Clinical relevance: Promising in heavily pretreated cHL.

Preliminary: Phase 1, small n.

Source: ASCO Abstract 7003

Epcoritamab + R-miniCVP — Elderly/frail DLBCL

Abstract 7002
● WatchPhase 2 · interimCD20×CD3 BsAbInterim futility

Indication: Elderly unfit/frail or anthracycline-ineligible newly diagnosed DLBCL

Key finding: CR after 6 cycles 86% (95% CI 65–97); 1-yr PFS 94.7% (68–99); CRS 55% (all G1).

Clinical relevance: Promising in the elderly/frail DLBCL population.

Preliminary: Interim futility analysis.

Source: ASCO Abstract 7002

VT-EBV-N — Post-remission EBV-CTL therapy

Abstract 7005
● WatchRandomized double-blind Phase 2EBV-specific T cells

Indication: EBV+ extranodal NK/T-cell lymphoma, post-remission

Key finding: 2-yr DFS 95.0% vs 77.6% (p=0.0347); deaths 0 vs 4 (16%); G≥3 AE 9.52% vs 16.00%.

Clinical relevance: A potential role for post-remission EBV-CTL therapy.

Source: ASCO Abstract 7005

R-da-EPOCH + Ibrutinib — HIV+ DLBCL

Phase 1/2
● WatchPhase 1/2BTK inh. + chemo

Indication: HIV-associated DLBCL

Key finding: ORR 100%; CR 57%; 3-yr EFS/OS 83%/81%; non-GCB 3-yr EFS/OS 76%/63%.

Clinical relevance: Adding ibrutinib to R-da-EPOCH is tolerable.

Source: ASCO Abstract (Phase 1/2)

Mediterranean CD19 Variants — CAR-T resistance genotyping

Abstract 7008
● WatchGenomic cohortCD19 genotypingNo clinical outcome data

Indication: B-cell malignancies, CAR-T resistance

Key finding: L174V (rs2904880) MAF 76.3%; V/V homozygosity 65.2%.

Clinical relevance: Potential for pre-CAR-T CD19 genotyping in the Mediterranean population.

Preliminary: No clinical outcome data; allele frequency only.

Source: ASCO Abstract 7008

frontMIND — Tafasitamab + lenalidomide + R-CHOP

LBA7000
● WatchPhase 3anti-CD19 + IMiD + chemoGated · full text unavailable

Indication: Newly diagnosed DLBCL

Key finding: Phase 3 results; full text 30 May 08:00 ET, not available in this digest's source.

Clinical relevance: Unclear; must be verified against the full text.

Gated: Numerical results not in this digest.

Source: ASCO Abstract LBA7000

🫁 Lung Cancer (NSCLC)

3 studies

Krascendo-170 — Divarasib + pembrolizumab (1L KRAS G12C+)

Abstract 8510
● Medium priorityPhase 1b/2KRAS G12C inh. + IO

Indication: 1L KRAS G12C+ NSCLC

Key finding: In the PD-L1+ cohort confirmed ORR 73% (95% CI 60–84), median PFS 19.3 mo (12.4–NE); in the PD-L1− cohort unconfirmed ORR 70%; G3/4 ALT increase 20%, AST 18%.

Clinical relevance: Phase 3 Krascendo 2 has been initiated.

Source: ASCO Abstract 8510

Elisrasib / D3S-001 — Mono and pembrolizumab combination (1L)

Abstract 8511
● Medium priorityPhase 1/2KRAS G12C inh.

Indication: 1L KRAS G12C+ advanced NSCLC

Key finding: Monotherapy ORR 78.0% (32/41); pembrolizumab combination ORR 81.2% (39/48); in the PD-L1 TPS ≥50% subgroup ORR 95.0%; 6-mo PFS 68.9% (mono) / 74.6% (combo); G≥3 TRAE mono 7.0%, combo 32.7%.

Clinical relevance: First promising evidence for G12Ci monotherapy in 1L.

Source: ASCO Abstract 8511

REVOL858R / WJOG14420L — Erlotinib + ramucirumab vs osimertinib

LBA8518
● WatchPhase 3Gated · full text unavailable

Indication: EGFR L858R-mutant 1L NSCLC

Key finding: Phase 3 comparison; full text was not available in the source.

Clinical relevance: Unclear; must be verified against the full text.

Gated: Numerical results not in this digest.

Source: ASCO Abstract LBA8518

⚕ Bladder & Renal Cancer

3 studies

KEYNOTE-905 / EV-303 — Perioperative EV + pembrolizumab (HRQoL)

Abstract 4510
● Medium priorityPhase 3 · HRQoLADC + anti-PD-1

Indication: Cisplatin-ineligible MIBC

Key finding: 18-wk post-op FACT-G change −2.73 vs −2.84 (no decrease vs control); BCI bowel/sexual scores worsened in both arms (sexual −15.46 vs −17.88).

Clinical relevance: Adding EV + pembrolizumab does not reduce HRQoL; given the efficacy benefit, it supports the risk/benefit profile.

Source: ASCO Abstract 4510

Adjuvant Pembrolizumab — Decision regret

Abstract 4512
● WatchSingle-arm PRODecision-regret scale

Indication: RCC after adjuvant pembrolizumab

Key finding: Mean DRS 14.9 (95% CI 8.5–21.3); 13% regret; long-standing/persistent toxicity associated with regret (26.9 LC vs 26.1 S vs 2.1 NS, p=0.0021); no difference CTCAE G1-2 vs G3-4 (p=0.23).

Clinical relevance: Long-term low-grade toxicity is the main driver of regret.

Source: ASCO Abstract 4512

RAMPART — Adjuvant durvalumab vs active monitoring (NEGATIVE)

LBA4511
● WatchPhase 3Did not improve DFS · Gated

Indication: Intermediate/high-risk resected RCC

Key finding: Adjuvant durvalumab monotherapy did not improve DFS versus active monitoring (full text 30 May 08:00 ET; numerical results were not available in the source, but the ASCO Daily News headline confirms the negative result).

Clinical relevance: Adjuvant durvalumab monotherapy appears to have no role in this setting.

Gated: Negative result confirmed at headline level; full statistics not in this digest.

Source: ASCO Abstract LBA4511

◐ Melanoma & Skin Cancer

2 studies

PIVOTAL — Neoadjuvant daromun (L19IL2/L19TNF)

LBA9517
● WatchPhase 3Intratumoral immunocytokineGated · full text unavailable

Indication: Resectable locally advanced melanoma

Key finding: Neoadjuvant daromun Phase 3 results; full text 30 May 08:00 ET, not available in the source.

Clinical relevance: Unclear; must be verified against the full text.

Gated: Numerical results not in this digest.

Source: ASCO Abstract LBA9517

MATRiX — Tuvusertib ± avelumab (Merkel cell carcinoma)

LBA9514
● WatchPhase 2ATR inh. ± anti-PD-L1Gated · full text unavailable

Indication: Anti-PD(L)-1-refractory Merkel cell carcinoma

Key finding: Tuvusertib ± avelumab Phase 2 results; full text was not available in the source.

Clinical relevance: Unclear; must be verified against the full text.

Gated: Numerical results not in this digest.

Source: ASCO Abstract LBA9514

🌍 Screening, Access & Care Delivery

4 studies

CIRCULATE-Japan GALAXY — ctDNA dynamics (CRC)

Abstract 102
● Medium priorityProspective cohortctDNA · patient selection

Indication: Resected stage I–IV colorectal cancer (CRC)

Key finding: In patients turning positive at the 2nd timepoint, adjuvant chemotherapy yielded DFS HR 0.3 (p=0.0165), 2-yr DFS 45.5% vs 9.8%; in those negative at both timepoints HR 0.8 (p=0.1744).

Clinical relevance: Early ctDNA dynamics may identify the subgroup that benefits from delayed ACT.

Source: ASCO Abstract 102

India — Community-based cervical cancer screening

Abstract 1509
● Medium priorityLongitudinal implementationHR-HPV self-sampling

Indication: Cervical cancer screening (global health)

Key finding: 1,747/1,869 (93.5%) HR-HPV self-sampling completed; HR-HPV 5.1% (89/1747); 71.9% colposcopy; 4 patients with high-grade lesions/early invasive cancer 100% referred to treatment.

Clinical relevance: A scalable model exceeding WHO elimination targets.

Source: ASCO Abstract 1509

Mexico — Immunotherapy access (real-world)

Abstract 1511
● WatchReal-world cohortAccess / supply chain

Indication: Various cancers, Mexican public center

Key finding: Of 228 immunotherapy-eligible patients, 114 (50%) were able to start; 42.1% could not start due to drug unavailability; 36.8% experienced treatment suspension; only 24.1% received guideline-concordant therapy.

Clinical relevance: An urgent need for supply-chain strategies.

Source: ASCO Abstract 1511

Ukraine — Clinical trial continuity under war conditions

Abstract 1512
● WatchOperational analysisResearch continuity

Indication: Oncology clinical research continuity

Key finding: 99% of planned patient visits and data transfers completed; 150 of 413 patients on active treatment/follow-up; 7,891 patient visits, 1,762 tumor response assessments.

Clinical relevance: Clinical research can continue in conflict zones with digital adaptation.

Source: ASCO Abstract 1512

⏳ Gated / Awaiting Full Text

Pivotal titles · Editorial

The following studies are accessible only behind a "Full text available May 30 08:00 AM ET" gate or at ASCO Daily News headline level; full statistics are not in this digest's source. Verify against the official presentation/publication full text. The relevant cancer type is tagged.
TALAPRO-3 (LBA5007)
Talazoparib + enzalutamide, HRR gene-altered mCSPC.
ProstateGated
RAMPART (LBA4511)
Adjuvant durvalumab vs active monitoring; did not improve DFS (negative).
Renal (RCC)Gated
NHS-Galleri (LBA100)
Multi-cancer early detection (MCED) test population screening, primary results.
Screening / MCEDGated
ESAONA (LBA2007)
Asandeutertinib vs osimertinib, EGFR-mutant NSCLC + brain metastases.
LungGated
FLAME (LBA101)
Osimertinib ± chemotherapy, persistent ctDNA EGFR+ NSCLC.
LungGated
Low-dose pembrolizumab + chemo (LBA1510)
Advanced NSCLC Phase 3.
LungGated
Cesium-131 vs SRS (LBA2000)
Brachytherapy comparison in newly diagnosed brain metastases.
CNS / BrainGated
SWOG S1823 (LBA5003)
miR-371 in early-stage testicular cancer.
TesticularGated
ASCO Daily News editorial highlights
Sunvozertinib (EGFR Exon20 NSCLC), BLUESTAR (B7-H4 ADC, gynecologic), Sac-TMT+Pembro, EV+Pembro — no text beyond headlines in the source.
MixedHeadline-level

This report was generated automatically and is not medical advice. Clinical decisions must be verified against official abstract/presentation full texts and current guidelines.

OncoHubOncoHub.ai · ASCO 2026 Gündem Bu içerik editoryaldir. Tıbbi tavsiye değildir. Klinik karar hekime aittir. oncohub.ai →